why choose us

First received: March 29, 2023

Clinical Trial: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myelofibrosis (PMF)

Study Type: INTERVENTIONAL


Official Title: Phase II Study of Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 120]

Brief Summary: This is an open label, phase II study to assess the efficacy, safety, and tolerability of Reparixin in patients with DIPSS intermediate-2, or high-risk primary myelofibrosis (PMF), post essential thrombocythemia/polycythemia vera related MF (Post ET/PV MF) after prior treatment, and those who are ineligible or refuse treatment, with a Janus kinase inhibitor (JAKi).26 patients will be enrolled.Eligible patients will receive oral reparixin three times daily on a 4-week cycle for a core study period of 6…

Read more